Marlborough biomanufacturing company Xcellerex Inc., along with three collaborators, has been awarded an $11 million government contract to develop technology for antibody and vaccine manufacturing.
The contract, from the Defense Threat Reduction Agency, is the second phase of a project that began with a 12-month contract from the Defense Advanced Research Projects Agency. Xcellerex, the prime contractor in the deal, is working with Dow Chemical Co., a division Dowpharma, Biopharm Services and deltaDOT on the project.
The second phase of the project involves improving the productivity and speed of a vaccine and antibody development process established in phase one.
